Services Design Development Scientific Advice Project Management QA – Quality Assurance Monitoring Clinical Performance Data Management/eTrials Biostatistics Medical Writing Expert Statement Expertise Pharmacokinetics BA/BE Interactions Oncological trials Ophthalmological trials Inhalatives Transdermal Therapeutic Systems Children Sexual Hormones Therapeutic Expertise Clinical Development Phase I Phase II / Proof of Concept Phase III in OTC Phase III Non-Interventional Magnetic Marker Monitoring Medical Devices Nutrition Studies Clinical Pharmacology Unit Location Plan Capacity Technical Monitoring Ophthalmology Gynaecology Intensive Assessment Unit Clean Room Area Archive About Us Goals and Visions Our Experts Science Quality Library Presentations Library Publications Locations Career News 22nd PKPD Expertentreffen in the heart of the Black Forest 3rd GBHI in Amsterdam: lively discussions and intensive exchange with authorities Meet us in Amsterdam: 3rd GBHI Conference starts soon (12 – 13 April 2018) Meet us in Munich: AGAH Annual Meeting 26 – 27 April 2018 Regorafenib: first in human as eye drops 3rd GBHI conference – all speakers confirmed Probanden The SocraTec Family SocraTec C&S SocraMetrics Cooperations
Product development Pharmacodynamic studies Drug Food Interaction Patch adhesion SocraTec C&S Pilot study COPD NIS CDASH Investigators brochure Allergy Recruitment rates Drug Drug Interaction Informed Consent Procedure Clinical trials CDSIC Phase IIa trials Dry eye Creativity Quality Dry powder inhaler MDI Sensitisation trials AGAH Quality Assurance Phase I Ophthalmologist GLP Data management Legal Information DDI Oncological patients Biosimilars Centralised procedure Ocular tolerability US FDA Charcoal Common cold Experience Bioequivalence CRF Legal representative FDA Copyright Hormone replacement therapy Authorities Cardiovascular surveillance SOP based Highly variable drugs CRA Phase III Data Management Plan Patients Gynaecological trials Slit lamp microscopy Thuringia First in human Inspection Xerostomia HRT Post authorisation Project Management Glaucoma Expert Local tolerability Phase I Unit Referral system Central surveillance system Oncologic network Dose linearity Statistical services GCP IEC OTC Consultancy CRO Bioavailability US CFR 21 Part 11 Subcontractor qualification Pragmatism Feasibility Adrenocortical Non interventional Clinical study Auditing Asthma Metered dose inhaler HTA Pituitary Axis IB Anaesthesiologist Ovulation inhibition Eye disease Monitoring EMA Sample size estimation Intensive assessment station Contraception Phase II Ophthalmology Immunogenicity Sore throat Pulse oximetry plethysmography IVIVC IMPD Macular MCID Pharmacology DUS Design development Rhine Main area Lung Quality Management System Phase IIb trials Biopharmaceutics Edema Statistical programming Absorption windows Source Data Verification WinNonlin Clinical development program TTS Good Clinical Practice Inhalatives Healthy subjects Safety PASS Degeneration Efficacy Uveitis Absorption Patch CDM HPA axis Transdermal therapeutic system Steady state Sequential designs Female adolescents Competence ICF Ophthalmological trials Children Network Standardisation DFI CDISC ADAM Biometrics Spacious archive Training Clinical pharmacology unit FIM Statistical Analysis Plan Dermal irritation Paediatricians Cough Pharmacokinetics SAS Early phase Hypothalamic Pharmacokintetics Elpro Scientific advice ANVISA Clinical Monitoring GCP training Protocol Phase IV Oncology Audit Protocol development PAES Postmenopausal women MMM Biopharmaceutical Data Validation Plan Endpoint Standard operating procedure SDV DPI Database Scientific expertise Patient recruitment Life cycle management In vitro in vivo correlation  
 
Menu

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
All fine on front page